Top Page
CSPC Pharmaceutical Group
(1093)
CSPC Pharmaceutical Group (1093) vs. iShares MSCI Hong Kong ETF (EWH)
CSPC Pharmaceutical Group Business Overview & Revenue Model
CSPC Pharmaceutical Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.22B | 29.54B | 31.47B | 31.59B | 27.41B | 23.58B |
| Gross Profit | 18.16B | 20.67B | 22.19B | 22.73B | 20.79B | 17.67B |
| EBITDA | 6.72B | 7.18B | 8.59B | 8.85B | 7.57B | 6.80B |
| Net Income | 4.07B | 4.41B | 5.88B | 6.22B | 5.51B | 4.88B |
Balance Sheet | ||||||
| Total Assets | 46.00B | 47.23B | 50.92B | 41.77B | 42.50B | 35.65B |
| Cash, Cash Equivalents and Short-Term Investments | 10.63B | 8.25B | 13.09B | 13.87B | 13.87B | 10.47B |
| Total Debt | 495.00M | 507.33M | 706.90M | 659.28M | 115.04M | 523.95M |
| Total Liabilities | 11.14B | 11.20B | 11.26B | 11.07B | 9.37B | 7.96B |
| Stockholders Equity | 33.25B | 34.33B | 36.53B | 29.77B | 31.79B | 26.48B |
Cash Flow | ||||||
| Free Cash Flow | 1.48B | 1.86B | 2.29B | 6.62B | 4.15B | 5.91B |
| Operating Cash Flow | 6.86B | 4.53B | 4.18B | 9.23B | 5.86B | 7.67B |
| Investing Cash Flow | -4.66B | -3.86B | 607.27M | -6.80B | -637.33M | -2.60B |
| Financing Cash Flow | -3.32B | -5.25B | -2.30B | -1.90B | -2.20B | -1.65B |
CSPC Pharmaceutical Group Technical Analysis
CSPC Pharmaceutical Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$235.79B | 44.86 | 16.09% | 0.94% | 8.68% | 0.82% | |
72 Outperform | HK$61.23B | 8.33 | 8.74% | 3.77% | -2.68% | -21.45% | |
63 Neutral | HK$86.50B | 20.81 | 11.30% | 3.00% | -18.07% | -33.27% | |
63 Neutral | HK$134.33B | 29.35 | 9.79% | ― | 16.90% | 63.11% | |
61 Neutral | HK$138.95B | 109.79 | 8.41% | ― | 52.78% | ― | |
54 Neutral | HK$115.18B | 28.85 | 11.72% | 1.39% | 13.69% | 50.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
CSPC Pharmaceutical Group Corporate Events
CSPC Pharmaceutical Group Limited has announced that its GLP-1/GIP receptor dual-biased agonist polypeptide injection, SYH2069, has received approval from the U.S. FDA to conduct clinical trials in the United States. This product, which is poised to be China’s first of its kind, shows promise in weight management and glycemic control for type 2 diabetes, demonstrating superior efficacy and safety in preclinical studies. The approval marks a significant step for CSPC in enhancing its position in the global pharmaceutical market, particularly in the field of metabolic diseases.
CSPC Pharmaceutical Group Limited has announced that its new chemical drug, SYH2056 tablets, a selective 5-HT2A receptor agonist, has received approval from the U.S. FDA to conduct clinical trials for treating major depressive disorder. This development marks a significant step as the drug has shown promising preclinical results, including rapid onset of action and reduced hallucination risks, positioning it as a potential best-in-class antidepressant. The approval highlights the company’s commitment to addressing the limitations of traditional antidepressants and meeting the broad clinical demand for novel therapies.
CSPC Pharmaceutical Group has announced the approval of its new drug, JMT206, for clinical trials in China. This recombinant fully human anti-ActRIIA/IIB monoclonal antibody is designed to aid in weight management for individuals with obesity or overweight conditions, showing promising efficacy and safety in preclinical studies. The approval marks a significant step in the company’s efforts to enhance its market position in the weight management sector.
CSPC Pharmaceutical Group Limited has announced that its independently developed double-stranded small interfering RNA drug, SYH2061 Injection, has received approval from the U.S. FDA to conduct clinical trials in the United States. This siRNA drug, which targets complement component C5, is designed for the treatment of IgA nephropathy and other complement-mediated diseases. The product has shown promising preclinical results, demonstrating superior pharmacological activity, long-lasting therapeutic effects, and a good safety profile, which could enhance the company’s positioning in the pharmaceutical market.
CSPC Pharmaceutical Group Limited has appointed Mr. QU Zhiyong as an Executive Director effective from November 21, 2025. Mr. QU, who has been with the company since 2004 and currently serves as the General Manager of the Hong Kong Head Office Management Centre, will bring his extensive financial expertise to the Board. This strategic appointment is expected to strengthen the company’s leadership and enhance its financial operations, potentially impacting its market positioning positively.
CSPC Pharmaceutical Group Limited has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides clarity on the leadership structure and governance, which could impact the company’s strategic direction and reassure stakeholders about its management stability.
CSPC Pharmaceutical Group has announced that its new chemical drug, SYH2056 tablets, a selective 5-HT2A receptor agonist, has received approval for clinical trials in China. This drug, aimed at treating depression, shows promise due to its rapid action, long-lasting effects, and reduced hallucination risk, potentially positioning it as a best-in-class antidepressant. The approval marks a significant step in addressing the limitations of traditional antidepressants and meeting the high clinical demand for novel depression therapies.
CSPC Pharmaceutical Group reported a 12.3% decrease in total revenue and a 7.1% decline in reported profit for the first nine months of 2025 compared to the previous year. The finished drugs segment, which experienced a 17.2% revenue drop, was notably impacted by industry policies like centralized volume-based procurement and drug price adjustments. Despite these challenges, the company saw growth in bulk products and functional foods, indicating a shift in market dynamics.
CSPC Pharmaceutical Group announced that its marketing authorization application for Pertuzumab Injection, a treatment for HER2-positive breast cancer, has been accepted by China’s National Medical Products Administration. The product has shown equivalence in efficacy and safety to existing treatments in clinical trials, potentially strengthening CSPC’s position in the oncology market.
CSPC Pharmaceutical Group Limited has announced a board meeting scheduled for November 20, 2025, to approve the unaudited third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder interests.
CSPC Pharmaceutical Group Limited announced the resignation of Mr. PAN Weidong as Executive Director and his replacement as the Authorized Representative by Dr. LI Chunlei. This change is part of the company’s ongoing management adjustments, which may influence its strategic direction and operational focus.
CSPC Pharmaceutical Group Limited has announced the composition of its Board of Directors, detailing the roles and functions of each member. This announcement is crucial for stakeholders as it outlines the leadership structure and governance, which can impact the company’s strategic direction and operational effectiveness.
CSPC Pharmaceutical Group Limited announced that its Executive Director, Mr. Pan Weidong, has been penalized by the China Securities Regulatory Commission for insider trading related to a restructuring transaction involving its subsidiary, CSPC Innovation Pharmaceutical Co., Ltd. Despite the penalty, the company maintains that its operations remain unaffected, and the incident is not expected to impact its business negatively.
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, released its unaudited financial results for the nine months ending September 30, 2025. The report highlights a 7.71% increase in operating revenue compared to the previous year, but also reveals significant net losses and a negative cash flow from operating activities. These financial challenges may impact the company’s operations and market positioning, urging caution among shareholders and potential investors.
CSPC Pharmaceutical Group has announced that its independently developed SYH2061 Injection, a double-stranded small interfering RNA drug, has received approval from China’s National Medical Products Administration for clinical trials. This drug, targeting complement component C5, is designed for treating IgA nephropathy and other complement-mediated diseases, offering long-lasting therapeutic effects and a promising clinical development value due to its superior pharmacological activity and safety profile.
CSPC Pharmaceutical Group announced that its drug JSKN003 has received another Breakthrough Therapy Designation from China’s National Medical Products Administration for treating HER2-positive advanced colorectal cancer. This designation highlights the drug’s promising efficacy and safety profile, potentially enhancing the company’s position in the oncology market and addressing significant unmet clinical needs in cancer treatment.
CSPC Pharmaceutical Group Limited announced the on-market purchase of 3,000,000 shares as part of its restricted share award scheme. This move, involving a total consideration of approximately HK$26,590,000, represents about 0.026% of the existing total number of shares in issue. The purchase is intended to benefit selected participants and reflects the company’s ongoing commitment to its share award scheme, potentially impacting its market positioning and stakeholder interests.
CSPC Pharmaceutical Group announced the on-market purchase of 4,496,000 shares as part of its restricted share award scheme. This move, representing approximately 0.039% of the total shares in issue, is intended to benefit selected participants and reflects the company’s ongoing commitment to employee incentives and shareholder value.
CSPC Pharmaceutical Group Limited announced the on-market purchase of 504,000 shares as part of its restricted share award scheme. This move, involving a total consideration of approximately HK$4,483,000, represents about 0.004% of the company’s existing shares and is intended to benefit selected participants, potentially enhancing stakeholder engagement and company performance.
CSPC Pharmaceutical Group Limited announced the on-market purchase of 6,000,000 shares as part of its restricted share award scheme, representing approximately 0.052% of the total shares in issue. This strategic move is aimed at benefiting selected participants and reflects the company’s ongoing commitment to incentivize and retain talent, potentially strengthening its market position and shareholder value.
CSPC Pharmaceutical Group Limited announced the on-market purchase of 3,000,000 shares as part of its restricted share award scheme, representing approximately 0.026% of the total shares in issue. This move is aimed at benefiting selected participants and reflects the company’s ongoing commitment to its share award scheme, potentially impacting its market positioning and stakeholder interests.
CSPC Pharmaceutical Group announced that its new drug application for Efmedaglutide Alfa Injection, aimed at long-term weight management in overweight or obese adults, has been accepted by China’s National Medical Products Administration. This acceptance, based on successful Phase III clinical trials, highlights the drug’s efficacy in reducing body weight and improving cardiovascular and metabolic parameters, with a favorable safety profile. The company is also conducting further trials for type 2 diabetes, potentially expanding its impact on patient care.
CSPC Pharmaceutical Group Limited has announced that its Tacrolimus Extended-release Capsules have received drug registration approval from China’s National Medical Products Administration. This approval enhances the company’s product portfolio in the area of immunological rejection, potentially strengthening its market position and offering new treatment options for graft rejection in kidney and liver transplant patients.
CSPC Pharmaceutical Group Limited has received approval from the U.S. FDA to conduct clinical trials for its new siRNA drug, SYH2070 Injection, in the United States. This drug, designed for liver-targeted delivery, shows promise in treating hypertriglyceridemia or mixed hyperlipidemia by effectively reducing ANGPTL3 levels. Preclinical studies indicate that SYH2070 offers superior pharmacological activity and a long-lasting therapeutic effect, positioning it as a potential leader in its category with significant clinical development value.
CSPC Pharmaceutical Group announced the proposed listing of its subsidiary, CSPC Innovation, on the Main Board of the Stock Exchange. This move is expected to reduce CSPC’s equity interest in CSPC Innovation by approximately 8.46%, constituting a discloseable transaction under the Listing Rules. The listing is subject to market conditions and regulatory approvals, and if successful, will involve an initial public offering of new H Shares, representing up to 10% of CSPC Innovation’s enlarged share capital. The announcement highlights CSPC’s strategic efforts to enhance its market presence and operational growth through this listing.
CSPC Pharmaceutical Group has announced that its new drug, SYH2070 Injection, has received approval from China’s National Medical Products Administration for clinical trials. This siRNA drug, designed for liver-targeted delivery to reduce ANGPTL3 levels, shows promise in treating hypertriglyceridemia and mixed hyperlipidemia, with preclinical studies highlighting its superior pharmacological activity and long-lasting effects compared to similar products, potentially enhancing the company’s position in the pharmaceutical market.
CSPC Pharmaceutical Group announced that its Lecanemab Injection has received approval from China’s National Medical Products Administration to conduct clinical trials. This marks the first biosimilar to lecanemab injection approved for clinical trials in China, aimed at treating mild cognitive impairment and mild Alzheimer’s disease dementia. The approval signifies a significant step in CSPC’s efforts to expand its market presence in the Alzheimer’s treatment sector.
CSPC Pharmaceutical Group Limited announced the grant of 9,000,000 restricted shares to an employee under its share award scheme. This initiative is designed to recognize the employee’s contributions and incentivize future performance in line with the company’s strategic goals. The shares will vest in four tranches from 2026 to 2029, contingent upon the achievement of specific performance targets. This move aims to retain talent and align employee interests with the company’s growth objectives.
CSPC Pharmaceutical Group announced that its subsidiary, AlaMab Therapeutics Inc., has received approval to conduct a Phase II clinical trial in China for ALMB-0166, a novel treatment for Parkinson’s disease. This first-in-class humanized monoclonal antibody inhibitor targets the Connexin 43 protein to provide neuroprotection by inhibiting neuroinflammatory mediators. The approval marks a significant step in addressing the urgent need for innovative treatments in Parkinson’s disease, potentially improving patient outcomes and positioning CSPC as a leader in neurological disorder therapies.
CSPC Pharmaceutical Group Limited has announced that its innovative SYH2066 Tablets have received approval from China’s National Medical Products Administration to commence clinical trials. This novel oral small molecule drug targets the respiratory syncytial virus (RSV) and is expected to become a significant therapeutic option, as there are currently no approved small molecule drugs for RSV globally. The approval marks a promising step in the company’s clinical development, potentially enhancing its industry position and offering new treatment possibilities for respiratory infections caused by RSV.
CSPC Pharmaceutical Group announced that its new drug application for KN026 (Anbenitamab Injection), co-developed with Jiangsu Alphamab Oncology, has been accepted by China’s National Medical Products Administration. This drug, an anti-HER2 bispecific antibody, is intended for the treatment of HER2-positive gastric cancer and has shown promising results in clinical trials, including improved survival rates and safety profiles. The acceptance marks a significant advancement in CSPC’s efforts to provide effective second-line treatments for gastric cancer, with ongoing trials for other solid tumors.